Download MendeleyAn Orally Active Bradykinin B1 Receptor Antagonist Engineered as a Bifunctional Chimera of Sunflower Trypsin Inhibitor.
Qiu, Y., Taichi, M., Wei, N., Yang, H., Luo, K.Q., Tam, J.P.(2017) J Med Chem 60: 504-510
- PubMed: 27977181
- DOI: https://doi.org/10.1021/acs.jmedchem.6b01011
- Primary Citation of Related Structures:
5H1H, 5H1I - PubMed Abstract:
An orally active and metabolically stable peptide TIBA was successfully engineered as a chimera by fusing an analgesic bradykinin receptor antagonist peptide and the trypsin inhibitory loop of sunflower trypsin inhibitor-1. As a fusion cyclic peptide, the metabolically labile analgesic peptide is protected from degradation by exopeptidases as well as the endopeptidases, and its serum half-life extended from <5 min to >6 h as a chimera. Moreover, the chimera TIBA was also found to be orally active in an animal pain model using a hot plate assay.
Organizational Affiliation:
School of Biological Sciences, Nanyang Technological University , 60 Nanyang Drive, 637551, Singapore.
